Metoclopramida Basi (Metoclopramide Hydrochloride Monohydrate)

• Metoclopramide is used to manage conditions related to nausea, vomiting and delayed gastric emptying.
• Nausea and vomiting: Reduces frequency and severity of acute and chemotherapy‑induced nausea and vomiting.
• Gastroparesis: Enhances gastric motility to improve stomach emptying in diabetic or idiopathic gastroparesis.
• Postoperative nausea and vomiting (PONV): Prevents and treats nausea and vomiting following surgical procedures.

• Metoclopramide antagonizes dopamine D2 receptors in the chemoreceptor trigger zone, diminishing the vomiting reflex. It also blocks peripheral D2 receptors in the gastrointestinal tract, promoting coordinated smooth‑muscle contractions that accelerate gastric emptying. Additional antagonism of 5‑HT3 receptors and modest anticholinergic activity contribute to its anti‑emetic and pro‑kinetic effects. The drug crosses the blood‑brain barrier, allowing central action, while its peripheral activity improves lower esophageal sphincter tone and reduces reflux.

Metoclopramide may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects

• Drowsiness: Feeling of sleepiness or fatigue.
• Restlessness or akathisia: Inner sense of unease prompting constant movement.
• Diarrhea: Loose, watery stools.
• Extrapyramidal symptoms: Muscle stiffness, tremor or involuntary movements, especially with higher doses.

Serious or Rare Side Effects

• Tardive dyskinesia: Persistent, irreversible involuntary facial or tongue movements.
• Neuroleptic malignant syndrome: Life‑threatening condition with fever, muscle rigidity and autonomic instability.
• Severe allergic reactions: Rash, itching, swelling, or anaphylaxis.
• Hyperprolactinemia: Elevated prolactin leading to galactorrhea or menstrual disturbances.

When prescribing Metoclopramide, clinicians should consider several safety precautions to minimize risks.

• Assess neurological history: Identify patients with Parkinson’s disease or seizure disorders before use.
• Limit duration: Use the lowest effective dose and avoid treatment longer than 12 weeks to reduce tardive dyskinesia risk.
• Monitor electrolytes: Check for hypokalemia or metabolic disturbances that may exacerbate gastrointestinal side effects.
• Caution in renal impairment: Adjust dosing or increase monitoring in patients with reduced kidney function.
• Avoid in infants: Not recommended for use in children under one month of age due to safety concerns.
• Store at room temperature: Keep in the original container, protect from moisture and light, and store below 25 °C.

Metoclopramide can interact with other medicines, altering its efficacy or increasing adverse effects.

Major Interactions (Avoid)

• Antipsychotics (e.g., haloperidol, chlorpromazine): Combined dopamine blockade may precipitate severe extrapyramidal reactions.
• MAO‑inhibitors: Concomitant use can enhance central nervous system side effects such as sedation and confusion.
• CYP2D6 substrates (e.g., codeine, tramadol): Metoclopramide may inhibit metabolism, increasing plasma concentrations of these agents.

Moderate Interactions (Monitor Closely)

• CNS depressants (e.g., benzodiazepines, opioids): May intensify drowsiness or sedation.
• Anticholinergic drugs (e.g., atropine, scopolamine): May reduce the pro‑kinetic benefit of metoclopramide.
• Serotonergic agents (e.g., ondansetron, SSRIs): Potential for additive effects on serotonin pathways.